Perioperative Pembrolizumab Expands in Bladder Cancer
Episode Summary
FDA expanded perioperative enfortumab vedotin plus pembrolizumab to cystectomy-eligible muscle-invasive bladder cancer, regardless of cisplatin eligibility, broadening pre- and postoperative treatment options.